The Salmon DNA Skincare Trend: What's Real, What's Risky, and What's Actually Legal Right Now

Polynucleotides and PDRN, Explained — The Regenerative Science Behind the Trend, and Why the Injectable Version Isn't Approved in the United States Yet

By Dr. Lazuk, Co-Founder and CEO of Dr. Lazuk Cosmetics® | Lazuk Esthetics® | Alpharetta, GA

I have had the same conversation more than a dozen times in the last two months.

A patient sits down for a consultation and says, "I saw something on TikTok about salmon DNA injections. People in Korea and the UK are getting them. Can I get that here?"

My answer is always honest, and it is always more complicated than a yes or no. Because the science behind what they are describing is genuinely interesting, and in some forms, genuinely well-supported. But the specific thing they saw on their phone — an injectable made from salmon DNA fragments — is not currently approved for use in the United States. And the gap between what is trending and what is legally and clinically available here is exactly the kind of gap that creates confusion, misinformation, and, occasionally, patients seeking out unregulated providers who are willing to inject something they should not be injecting.

I want to walk through this carefully, the way I do with patients in my office in Alpharetta. Not to dismiss the trend — there is real biology here worth understanding — but to separate what is established, what is promising but unproven, and what is simply not legally available to you right now, regardless of what an Instagram ad or a med spa in another country is offering.

What Polynucleotides Actually Are

Polynucleotides, often abbreviated PN, are long chains of nucleotides — the basic building blocks of DNA — extracted and purified from biological sources. In the overwhelming majority of commercial and clinical formulations, that source is salmon or trout sperm DNA, chosen because its molecular structure is remarkably similar to human DNA while being abundant, inexpensive to source as a byproduct of the fishing industry, and well-characterized in terms of purification and safety processing.

Polydeoxyribonucleotide, or PDRN, is a related but distinct compound. It is a lower-molecular-weight fragment derived from the same polynucleotide source material. The distinction matters clinically: PDRN's smaller fragments are absorbed and metabolized differently than the longer-chain PN molecules, and the two have somewhat different evidence bases and approved uses depending on the country and regulatory body involved.

Both compounds are purified extensively before use. The DNA fragments are not "live" in any meaningful biological sense — they do not carry genetic information that integrates into your cells or alters your genome. What they do is something more specific and, frankly, more interesting from a regenerative medicine standpoint.

The Mechanism: Why This Isn't Just Marketing Language

Here is where I want to slow down, because this is the part that gets flattened into a soundbite on social media and loses all of its nuance.

PDRN and PN work through two complementary mechanisms that have been studied in laboratory and clinical settings.

The first is called the salvage pathway. When PDRN is introduced into tissue, it is broken down by naturally occurring enzymes into smaller nucleosides and nucleotides. Cells in the area can absorb these smaller units and use them as raw material to synthesize new DNA and repair damaged DNA — essentially recycling these molecular building blocks rather than manufacturing them from scratch. This is a real, well-documented cellular process, not a marketing invention.

The second mechanism involves a specific cell surface receptor called the adenosine A2A receptor. PDRN and PN have a particular affinity for this receptor, and when they bind to it, they trigger a signaling cascade inside the cell. This cascade has several downstream effects that are directly relevant to skin: it promotes the proliferation of fibroblasts, the cells responsible for producing collagen and elastin; it stimulates angiogenesis, the formation of new small blood vessels that improve circulation and nutrient delivery to the treated area; and it reduces the activity of pro-inflammatory cytokines, the signaling proteins that drive local inflammation.

Put simply: this is not just hydration, and it is not just a trendy ingredient riding on novelty. There is a specific, receptor-mediated mechanism by which these molecules can plausibly support tissue repair, reduce localized inflammation, and stimulate the kind of fibroblast activity that underlies collagen production. That is precisely why this category has captured the attention of both the regenerative aesthetics community and, increasingly, my own patients.

What the Actual Research Shows

I want to be precise about the state of the evidence, because this is where a lot of consumer-facing content either overstates or understates what we actually know.

There is a meaningful and growing body of peer-reviewed research on PDRN and PN. Studies have examined their use in wound healing, where the regenerative and anti-inflammatory properties have shown genuine clinical benefit, particularly in dermatology and in the management of chronic wounds. There is published research — including a prospective observational study on polynucleotide injections for periorbital rhytides, the fine lines around the eyes — showing measurable improvement in skin texture, hydration, and fine line appearance following a series of treatments.

Other studies have looked at long-chain polynucleotide fillers and demonstrated improvements in pore size, skin texture, fine wrinkles, and skin laxity, with a favorable side effect profile compared to some other injectable categories. Laboratory research has also examined polynucleotides derived from non-animal sources — including a notable study on microbial-derived PDRN as a sustainable alternative to the traditional salmon-based extraction — suggesting the field is actively working on supply and sourcing improvements as demand grows.

What I want patients to understand is the difference between "there is real science here" and "this is a proven, FDA-validated treatment with the same evidence base as something like hyaluronic acid fillers, which have decades of data behind them." PDRN and PN are a genuinely promising and actively researched category. They are not yet a treatment with the depth of long-term, large-scale clinical evidence that some of the older, more established categories in aesthetic medicine have accumulated. Promising and proven are not the same word, and a responsible practice should never blur that line for you.

The Part Nobody Wants to Say Clearly: The U.S. Legal Status

This is the section I consider the most clinically important part of this entire conversation, because it is the part most likely to actually protect you from harm.

As of now, injectable polynucleotide and PDRN products — the category that includes well-known international brand names that circulate heavily on social media — do not have FDA approval for injection in the United States. This is true regardless of how widely they are used in South Korea, the United Kingdom, parts of Europe, or other markets with different regulatory pathways. A product being legally injectable in Seoul or London does not make it legally injectable in Atlanta, and any provider telling you otherwise is giving you inaccurate information.

There is one important and specific exception worth knowing: a topical polynucleotide product has received FDA clearance in the United States, but specifically for topical application, most commonly delivered via microneedling, not via injection. This distinction is not a technicality. It is the entire difference between a compliant, regulated treatment delivered by a licensed provider using an approved delivery method, and an off-label or outright illegal injection using a product that has not gone through the FDA's safety and efficacy review process for that use.

I say this directly because I think patients deserve directness: if a provider in the United States is offering you an injectable "salmon DNA" or "PDRN" treatment, I would ask them, specifically, what product they are using, what its FDA status is for injectable use, and where they sourced it. Vague or evasive answers to that question are a meaningful red flag. Unapproved injectable products carry real risks — including unknown sterility standards, unknown purification consistency, unknown dosing accuracy, and the absence of the adverse event reporting infrastructure that comes with FDA-regulated products. This is not bureaucratic caution for its own sake. It is the actual mechanism by which patients are protected from contaminated, mislabeled, or inconsistently manufactured biologic products.

Why This Trend Exploded the Way It Did

Understanding why this became such a significant social media moment helps explain both the appeal and the risk.

The trend has clear roots in South Korea, where polynucleotide and PDRN treatments have an established place in the aesthetic medicine landscape and a regulatory pathway that differs from the FDA process. K-beauty content has long had outsized influence on global skincare trends, and as regenerative aesthetics — treatments that work by stimulating the body's own repair processes rather than simply filling or relaxing — became the dominant philosophical shift in the aesthetics industry, PDRN and PN were a natural next chapter in that story, following closely behind the rise of exosome-based treatments, which I have written about separately because the two categories get confused with each other constantly despite being biologically distinct.

Social platforms amplified it further because the visual narrative is compelling: a treatment derived from fish DNA, marketed with phrases like "glass skin" and "second skin," delivered via a quick in-office procedure, with before-and-after content that performs well in short-form video. The ingredient story itself — DNA from salmon, repairing human skin — has the kind of counterintuitive, slightly startling quality that drives shares and comments, independent of the underlying clinical reality.

None of that makes the underlying science illegitimate. But it does mean that the volume and intensity of consumer interest significantly outpaced the regulatory and clinical infrastructure required to deliver it safely and legally in every market, including ours. That mismatch is precisely the situation that creates space for unregulated providers, medical tourism risk, and patients making decisions based on incomplete information.

What You Can Actually, Legally Access Right Now

This is the question my patients actually want answered, so let me answer it plainly.

Topical PDRN-containing formulations, applied either as a standalone topical or — more effectively — delivered via microneedling, represent the compliant, evidence-supported way to access this category of ingredient in the United States today. Microneedling creates controlled micro-channels in the skin that significantly improve the penetration and bioavailability of topically applied PDRN, allowing the molecule meaningful access to the dermal layers where its regenerative signaling can have an effect, without crossing into unapproved injectable territory.

This approach also allows for thoughtful combination with other actives. Research and clinical experience both support pairing PDRN with vitamin C and niacinamide, which enhance antioxidant protection and help preserve the extracellular matrix the PDRN is working to support. This is consistent with a broader principle I apply across every regenerative treatment I offer: these technologies work best as part of a coordinated strategy, not as an isolated miracle step.

For patients specifically interested in injectable biostimulation — treatments designed to stimulate the skin's own collagen production through a different, FDA-compliant mechanism — there are well-established, approved options I discuss individually based on each patient's skin quality, goals, and timeline. The right comparison is not "PDRN injections versus nothing." It is "PDRN injections, which are not currently legal here, versus the FDA-approved regenerative and biostimulatory options that are legal here and have a more established evidence base." Patients are almost always relieved to learn that "not yet approved" does not mean "no good options exist."

How PDRN Compares to Other Regenerative Categories

Patients frequently ask how this fits alongside the other regenerative treatments they have heard about, so I want to place it in context.

Exosomes, which I have covered in detail in a previous piece, are extracellular vesicles — tiny membrane-bound packages released by cells — that carry growth factors, proteins, and signaling molecules between cells. They work through a broader and more complex signaling mechanism than PDRN's more targeted adenosine receptor pathway. Both categories fall under the umbrella of regenerative aesthetics, but they are biologically distinct, derived differently, and regulated differently. Neither is simply a "better" or "worse" version of the other; they are different tools with different evidence bases and different current legal pathways in the United States.

Platelet-rich plasma, or PRP, uses the patient's own blood, concentrated to isolate platelets rich in growth factors, then reintroduced into the treatment area. PRP has a substantially longer track record in aesthetic and orthopedic medicine, a well-established safety profile because it uses autologous material, and broad acceptance as an in-office procedure. It is not a competitor to PDRN so much as a different point on the same regenerative spectrum — one that happens to have a more mature regulatory and evidence history in this country specifically.

Biostimulatory injectables, a separate and FDA-approved category, work by triggering a controlled inflammatory and collagen-synthesis response through a different biochemical pathway entirely. For patients prioritizing legally available injectable collagen stimulation today, this category, combined with energy-based skin tightening modalities where appropriate, often represents the most clinically appropriate current option.

I walk through these comparisons with patients individually because the right answer genuinely depends on skin quality, treatment history, goals, and timeline — not on which option is currently generating the most social media attention.

Who Should Be Curious, and Who Should Wait

For patients who are simply curious about regenerative skincare ingredients and want to incorporate well-supported, legally available options into a topical routine, PDRN-containing serums and microneedling-delivered formulations are a reasonable and low-risk place to start, particularly when layered into a barrier-supportive, antioxidant-rich routine.

For patients specifically seeking the injectable version they encountered on social media, my honest clinical guidance is to wait. Not because the underlying science is illegitimate, but because the specific product category they are asking about does not currently have a legal, regulated pathway for injectable use in the United States, and pursuing it through unregulated channels — including medical tourism specifically for this treatment, or seeking out providers willing to inject unapproved products domestically — introduces real and avoidable risk for a benefit that has not yet been established to the standard we require for the other injectables I do offer.

This is, admittedly, not the answer that generates excitement. But it is the honest one, and I would rather tell a patient "this isn't appropriately available yet, and here is why" than perform a procedure I cannot stand behind with full confidence in its safety profile.

The Strategic Framework I Use With Patients

When a patient brings this topic to me, I walk through it in three tiers, the same way I approach most regenerative aesthetics conversations.

Foundational: a properly formulated topical routine, including barrier-supportive moisturizers, broad-spectrum sun protection, and antioxidant serums, remains the non-negotiable baseline regardless of which regenerative trend is currently popular. No injectable or device-based treatment, PDRN included, substitutes for this groundwork. Skin that is well-protected and well-hydrated responds better to every subsequent intervention.

Supportive: for patients wanting to explore PDRN's regenerative properties through a compliant delivery method, topical PDRN combined with microneedling is the appropriate current tier. This delivers genuine, research-supported benefit to skin texture, hydration, and the dermal environment, without venturing into unapproved injectable territory.

Corrective: for patients seeking more significant collagen stimulation, volume support, or skin tightening through injectable or energy-based methods, I direct them toward the FDA-approved biostimulatory, PRP-based, or energy-device options that are appropriate to their specific presentation — categories with a more established safety and efficacy record in this country today.

This framework will likely shift over time. Regulatory pathways evolve, and it is entirely possible that injectable PDRN or PN formulations receive U.S. approval in the coming years as more data accumulates. When and if that happens, I will incorporate it into the corrective tier with the same evidence-based scrutiny I apply to every other treatment in my practice. Until then, I would rather give patients an honest, current answer than a hopeful but inaccurate one.

A Note on Sourcing and Sustainability

One detail patients rarely ask about, but that I think is worth mentioning, is sourcing. Traditional PDRN and PN extraction relies on salmon or trout sperm as a byproduct of the fishing industry, which raises reasonable questions about scalability as demand grows globally. Recent research has begun exploring microbial-derived alternatives — polydeoxyribonucleotide produced through fermentation rather than animal extraction — as a more sustainable and potentially more consistent source material going forward. This is a space worth watching, both for sustainability reasons and because more consistent manufacturing processes tend to correlate with more consistent clinical outcomes and, eventually, smoother paths through regulatory review.

What I Tell Patients in Alpharetta, Johns Creek, Milton, and Cumming

I see this question constantly across the North Atlanta communities I serve, and I want to be consistent in how I answer it, whether you are asking me in person or reading this online.

The biology behind polynucleotides and PDRN is genuinely interesting and, in the right delivery method, genuinely useful. The injectable version that dominates social media content from Korea and the UK is not currently a legal option here, and I will not perform a procedure outside that framework, regardless of patient interest, because the absence of FDA approval for injectable use is not a minor technicality — it reflects a genuine gap in the safety and efficacy data required before I am willing to put something into a patient's skin.

What I can offer, today, compliantly and with confidence, is a topical and microneedling-delivered approach that captures meaningful elements of this regenerative mechanism, layered into a broader strategy that includes the FDA-approved biostimulatory and energy-based options with a more established track record. That combination, in my experience, delivers real results without asking a patient to accept a risk profile I am not willing to stand behind.

The skin underneath all of this — yours — deserves treatments chosen because the evidence supports them, not because they performed well in a fifteen-second video. That is the standard I hold every recommendation in this practice to, and it is the standard I would encourage you to hold any provider to, regardless of how compelling the trend looks on your phone.

May your skin always glow as brightly as your smile!

~ Dr. Lazuk CEO & Co-Founder Dr. Lazuk Cosmetics® | Lazuk Esthetics® Alpharetta, GA | Johns Creek, GA | Milton, GA | Suwanee, GA

If you're in Alpharetta, Johns Creek, or the North Atlanta area and want to explore compliant, physician-led regenerative skincare with Dr. Lazuk, our team at Lazuk Esthetics® offers personalized treatments tailored to your specific skin and goals.

Entertainment-only medical disclaimer: This content is for educational and entertainment purposes only and is not intended as medical advice. Individual skin needs vary and should be evaluated by a licensed professional. FDA approval status of specific products and treatments is subject to change; patients should always confirm current regulatory status directly with their provider.

FAQs — Polynucleotides, PDRN, and Salmon DNA Skincare

1. What are polynucleotides, exactly?

Polynucleotides, often abbreviated PN, are purified, long-chain DNA fragments most commonly extracted from salmon or trout sperm, chosen for their structural similarity to human DNA. They are used in regenerative skincare and aesthetic medicine for their tissue-repair and anti-inflammatory signaling properties, not as a source of genetic material that alters your own DNA.

2. What is PDRN, and how is it different from PN?

PDRN, or polydeoxyribonucleotide, is a lower-molecular-weight fragment derived from the same source material as PN. The shorter chain length affects how it is absorbed and metabolized in tissue, and the two compounds have somewhat different evidence bases and approved uses depending on the regulatory environment.

3. Is this actually salmon sperm, and is that safe?

Yes, the source material for most commercial polynucleotide and PDRN products is salmon or trout sperm DNA, extensively purified before use. The purification process removes the material's biological "liveliness," meaning it does not carry functional genetic information into your cells. Safety depends heavily on manufacturing quality and regulatory oversight of the specific product.

4. How does PDRN actually work on skin?

PDRN works through two main mechanisms: the salvage pathway, in which cells break PDRN down into smaller units and reuse them as raw material for DNA repair, and binding to adenosine A2A receptors, which triggers a signaling cascade that promotes fibroblast activity, supports new blood vessel formation, and reduces inflammatory signaling.

5. Is PDRN the same thing as exosomes?

No. They are both part of the broader regenerative aesthetics category, but they are biologically distinct. Exosomes are cell-derived vesicles carrying a complex mixture of growth factors and signaling molecules, while PDRN is a purified DNA fragment working primarily through the salvage pathway and adenosine receptor signaling. They are not interchangeable, and claims that conflate them are inaccurate.

6. Can I legally get PDRN injections in the United States?

Currently, injectable polynucleotide and PDRN products do not have FDA approval for injectable use in the United States, regardless of their availability in South Korea, the United Kingdom, or other markets. One topical polynucleotide product has received FDA clearance specifically for topical application, typically delivered via microneedling.

7. Why is this legal in Korea and the UK but not in the U.S.?

Different countries have different regulatory bodies and approval pathways, and a product's approval in one country's system does not transfer to another's. The FDA requires its own review of safety and efficacy data before authorizing a product for a specific use in the United States, and injectable PDRN and PN products have not yet completed that process here.

8. What happens if I get an injection that isn't FDA-approved?

Unapproved injectable products carry meaningfully elevated risk because they have not gone through the FDA's sterility, purity, dosing-consistency, and adverse-event-reporting review process. This means there is less assurance around manufacturing consistency and a less established system for tracking and responding to complications, compared to FDA-approved injectables.

9. What can I actually do right now if I'm interested in this category?

Topical PDRN-containing serums, particularly when delivered via microneedling to improve penetration into the dermis, represent the compliant and evidence-supported way to access this ingredient category in the United States today, often combined with vitamin C and niacinamide for enhanced antioxidant and barrier support.

10. Does microneedling with PDRN actually work, or is it just hydration?

Research on PDRN's mechanism, including its action on the adenosine A2A receptor and the salvage pathway, supports effects beyond simple surface hydration, including fibroblast stimulation and reduced local inflammation. Clinical studies, including research on periorbital rhytides, have shown measurable improvement in skin texture and fine lines with a topical and microneedling-based approach.

11. How does PDRN compare to PRP?

PRP uses a patient's own concentrated blood platelets and has a substantially longer clinical track record and more established regulatory acceptance in the United States. PDRN works through a different, receptor-mediated mechanism and currently has a more limited but actively growing evidence base for legally available delivery methods here.

12. Will injectable PDRN ever be approved in the U.S.?

It's possible. Regulatory pathways evolve as more clinical data accumulates, and global interest in this category continues to grow the available research base. If and when injectable approval occurs, it would be reasonable to reassess this treatment category, the same way any responsible practice reassesses its protocols as new approved options become available.

13. Are there sustainable alternatives to salmon-derived PDRN?

Yes. Recent research has explored microbial-derived, fermentation-based PDRN as a more sustainable and potentially more consistent alternative to traditional animal-sourced extraction. This is an active area of development that may also support more consistent manufacturing quality going forward.

14. What should I ask a provider offering "salmon DNA" treatments?

Ask specifically what product they are using, its FDA status for the exact delivery method being offered (topical versus injectable), and where the product is sourced. Vague, evasive, or reassuring-without-specifics answers to these questions are a meaningful red flag, regardless of how the treatment is marketed.

15. Who is a good candidate for PDRN-based topical or microneedling treatment?

Most patients interested in regenerative skincare with reasonable skin barrier function and no active skin infection or uncontrolled inflammatory skin condition are reasonable candidates for topical PDRN delivered via microneedling. As with any treatment, individual candidacy should be assessed during a consultation that accounts for your specific skin history and goals.